|
Real-time Estimate
Cboe BZX
10:33:34 05/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 28.82 USD | -3.69% |
|
-2.71% | +7.07% |
| 23/09 | Top Midday Decliners | MT |
| 23/09 | Celldex Therapeutics, Inc. - Special Call |
| Market Cap | 235.04Cr 209.44Cr 192.07Cr 174.55Cr 328.14Cr 22TCr 335.64Cr 2.3TCr 920.27Cr 12TCr 882.22Cr 863.34Cr 37TCr | P/E 2026 * |
-7.13x | P/E 2027 * | -6.99x |
|---|---|---|---|---|---|
| Enterprise Value | 168.81Cr 150.42Cr 137.95Cr 125.36Cr 235.67Cr 16TCr 241.06Cr 1.65TCr 660.95Cr 8.44TCr 633.62Cr 620.06Cr 27TCr | EV / Sales 2026 * |
913x | EV / Sales 2027 * | 195x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CLDX | Delayed | |
CBOE
| CLDX | Real-time | |
|
Börse Stuttgart
| TCE2 | Delayed | |
|
Tradegate
| TCE2 | Real-time | |
|
Deutsche Boerse AG
| TCE2 | Delayed | |
|
Berne S.E.
| TCE1 | End-of-day quote | |
|
Boerse Muenchen
| TCE2 | Real-time |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | -3.64% | ||
| 1 week | -1.66% | ||
| Current month | -2.34% | ||
| 1 month | -9.80% | ||
| 3 months | -28.41% | ||
| 6 months | -13.19% | ||
| Current year | +8.23% |
| 1 week | 28.61 |  | 30.92 |
| 1 month | 27.46 | | 32.68 |
| Current year | 22.33 | | 45.14 |
| 1 year | 22.1 | | 45.14 |
| 3 years | 14.4 | | 53.18 |
| 5 years | 14.4 | | 53.18 |
| 10 years | 1.5 | | 75.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 25/06/26 | Free | Executive/Senior Manager | 20,000 | 0.0255% | ||
| 25/06/26 | Free | Director | 26,000 | 0.0331% | ||
| 25/06/26 | Free | Chief Technology Officer | 57,000 | 0.0726% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.11% | -1.66% | +23.87% | +0.15% | 235.04Cr | |
| +3.80% | +8.47% | +64.65% | +77.70% | 6.69TCr | |
| +1.72% | +5.06% | +25.04% | +103.14% | 5.65TCr | |
| +0.17% | +1.29% | +12.63% | +76.44% | 5.72TCr | |
| +0.27% | -3.70% | +26.07% | +33.51% | 4.35TCr | |
| -7.72% | -3.29% | +210.10% | +754.29% | 4.28TCr | |
| +4.90% | +6.74% | +23.40% | +102.20% | 4.3TCr | |
| +1.86% | -3.75% | +98.26% | +82.12% | 3.21TCr | |
| +7.50% | +13.28% | +28.05% | +64.46% | 3.4TCr | |
| -2.24% | -2.77% | -41.94% | +355.12% | 2.41TCr | |
| Average | +0.53% | +3.67% | +47.01% | +164.91% | 4.02TCr | |
| Weighted average by Cap. | +1.13% | +3.89% | +51.55% | +166.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 18.5L 16.48L 15.12L 13.74L 25.83L 17Cr 26.42L 1.81Cr 72.43L 9.25Cr 69.44L 67.95L 29Cr | 87.6L 78.06L 71.58L 65.05L 1.22Cr 83Cr 1.25Cr 8.56Cr 3.43Cr 44Cr 3.29Cr 3.22Cr 138.8Cr |
| Net income | -32Cr -28Cr -26Cr -24Cr -45Cr -3.02TCr -46Cr -311.74Cr -124.97Cr -1.6TCr -119.8Cr -117.24Cr -5.06TCr | -36Cr -32Cr -29Cr -27Cr -50Cr -3.41TCr -52Cr -352.53Cr -141.32Cr -1.81TCr -135.48Cr -132.58Cr -5.72TCr |
| Net Debt | -66Cr -59Cr -54Cr -49Cr -92Cr -6.26TCr -95Cr -646.89Cr -259.33Cr -3.31TCr -248.6Cr -243.28Cr -10TCr | -64Cr -57Cr -52Cr -47Cr -89Cr -6.04TCr -91Cr -623.83Cr -250.08Cr -3.19TCr -239.74Cr -234.61Cr -10TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/26/05 | $29.06 | -2.91% | 2,62,361 |
| 04/26/04 | $29.93 | +0.74% | 9,11,485 |
| 03/26/03 | $29.71 | +2.31% | 8,72,044 |
| 02/26/02 | $29.04 | -3.52% | 9,56,133 |
| 30/26/30 | $30.10 | +0.70% | 8,70,776 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CLDX Stock
Select your edition
All financial news and data tailored to specific country editions
